期刊文献+

阿尔茨海默病与轻度认知障碍患者血浆sCD40及sCD40L浓度研究 预览 被引量:3

The study of plasma levels of sCD40 and sCD40L in Aizheimer' s disease and mild cognitive impairment
在线阅读 下载PDF
分享 导出
摘要 目的探索阿尔茨海默病(Alzheimer’Sdisease,AD)及遗忘型轻度认知障碍(amensticmildcognitiveimpairment,aMCI)患者血浆可溶性CD40(solubleCD40,sCD40)和可溶性CD40配体(solubleCD40ligand,sCD40L)浓度变化特点及其临床意义。方法采用酶联免疫吸附法检测20例AD患者、35例aMCI患者和32名正常对照者血浆sCD40和sCD40L浓度水平,简易精神状态检查表(mini—mentalstateexamination,MMSE)评估患者认知功能。结果AD组、aMCI组和对照组血浆sCD40浓度中位数(上下四分位数)分别为[123.3(97.4,149.5)pg/mL]、[102.9(63.6,124.0)pg/mL]和[70.66(51.0,90.8)pg/mL],3组间sCD40浓度差异均有统计学意义(P〈0.05)。AD组、aMCI组和对照组血浆sCD40L浓度中位数(上下四分位数)分别为[537.0(316.0,1134.O)pg/mL]、[316.0(190.0,546.0)pg/mL]和[167.O(107.5,478.0)ps/mL],3组间sCD40L浓度差异均有统计学意义(P〈O.05)。aMCI组血浆sCD40L浓度与MMSE得分呈负相关(r=0.74,P〈0.01)。结论sCD40和sCD40L浓度水平在AD和aMCI患者血浆中异常增高,因此sCD40和sCD40L可作为AD的早期检测指标,并提示CD40-CD40L信号可能参与AD的发生发展。 Objective To explore the plasma levels of soluble CD40 (sCD40) and soluble CD40 ligand (sCD40L) in the patients with Alzheimer' s disease (AD) and those with amnestic mild cognitive impairment (aMCI). Methods The levels of plasma sCD40 and sCD40L were measured in 20 patients with AD, 35 patients with aMCI, and 32 cognitively normal controls (NC) using commercially available ELISAs. The cognitive function of AD and aMCI patients was mea- sured by mini-mental state examination (MMSE). Results There were significant differences in plasma sCD40 among AD, aMCI and NC groups (P〈0.05) as the medians (the upper and lower quartiles) of plasma levels were 123.3 (97.4, 149.5) pg/mL, 102.9 (63.6, 124.0) pg/mL and 70.66 (51.0, 90.8) pg/mL, respectively. There were significant differences in plasma sCD40L among AD, aMCI and NC groups (P〈0.05) as plasma levels were 537.0 (316.0, 1134.0) pg/mL, 316.0(190.0,546.0) pg/mL and 167.0 (107.5,478.0) pg/mL. A negative correlation between the plasma concentrations of sCD40L and the MMSE scores was found in aMCI patients (t=-0.736,/9〈0.001). Conehtslons There are relevant chang- es of plasma sCD40 and sCD40L levels in patients with AD and aMCI. The present results suggest that plasma levels of sCD40 and sCD40L may be appropriate biomarkers for AD patients and indicate that CD40-CD40L signaling may be in- volved in AD pathophysiology.
作者 李玲 钟笑梅 施海姗 候乐 罗新妮 王艳华 胡国艳 陈辛茹 张蔚茹 陈贲 彭琪 宁玉萍 Li Ling, ZHONG Xiaomei, SHI Haishan, HOU Le, LUO Xinni, WANG Yanhua, HU Guoyan, CHEN Xinru, ZHANG Wenru, CHEN Ben, PENG Qi, NING Yuping( Department of Guangzhou Brain Hospital, Guangzhou 510000, China. )
出处 《中国神经精神疾病杂志》 CAS CSCD 北大核心 2016年第8期460-464,共5页 Chinese Journal of Nervous and Mental Diseases
基金 国家自然科学基金(编号:30970902) 广州市医药卫生科技项目(编号:2014A011044) 广州市脑科医院广州市医学重点学科建设项目子项目(编号:GBH2014-QN03)
关键词 阿尔茨海默病 遗忘型轻度认知障碍 可溶性CD40 可溶性CD40L Alzheimer's Disease Amnestic mild cognitive impairment sCD40 sCD40L
作者简介 通信作者(E-mail:ningjeny@126.com)
  • 相关文献

同被引文献11

引证文献3

二级引证文献3

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈